Core Viewpoint - The company expects a profit decrease of approximately 37% for the six months ending June 30, 2025, compared to the same period in 2024 due to changes in industry conditions and adjustments in product marketing strategies [1] Group 1 - The anticipated profit decline is primarily attributed to a shift in industry dynamics [1] - The company's adjustments in marketing strategies have led to a reduction in purchases by customers and distributors in the first half of 2025 [1] - As a result, both sales and profits for the first half of 2025 are expected to decline [1]

Core Viewpoint - The company, Jin Sang Zi (06896), anticipates a profit decrease of approximately 37% for the six months ending June 30, 2025, compared to the same period in 2024, primarily due to changes in industry conditions and adjustments in product marketing strategies [1] Group 1 - The expected profit decline is attributed to a reduction in purchases by customer distributors in the first half of 2025 [1] - The company's sales and profit are projected to decline as a result of the aforementioned factors [1]

Group 1 - The company expects a profit decrease of approximately 37% for the six months ending June 30, 2025, compared to the same period in 2024 [1] - The profit decline is primarily attributed to changes in industry conditions and adjustments in the company's product marketing strategy [1] - As a result of these changes, customer distributors reduced their purchases in the first half of 2025, leading to a decline in both sales and profit for the company [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 GOLDEN THROAT HOLDINGS GROUP COMPANY LIMITED 6896 盈利預警 - 1 - 本公司股東及有意投資者於買賣本公司股份時，務須審慎行事。 承董事會命 金嗓子控股集團有限公司 主席 江佩珍 中華人民共和國，廣西 2025年8月11日 於本公告日期，董事會成員包括非執行董事江佩珍女士；執行董事曾勇先生、黃建平先 生、曾克雄先生及何錦強先生；及獨立非執行董事李驊先生、朱頡榕先生、程益群先生 及覃解生先生。 本公告由金嗓子控股集團有限公司（「本公司」，連同其附屬公司稱為「本集團」）根據香港 法例第571章證券及期貨條例第XIVA部項下之內幕消息條文及香港聯合交易所有限公司 證券上市規則第13.09條而作出。 本公司董事會（「董事會」）謹此宣佈，根據初步評估本集團截至2025年6月30日止六個月之 未經審核中期綜合財務報表及董事會目前可得資料，與2024年同期比較，截至2 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06896 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | USD | | 0.000025 | USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | | USD | | 0 | | 本月底結存 | | | 2,000,000,000 | USD | | 0.000025 | USD | | 50,000 | 本月底法定/註冊股本總額： USD 50,000 第 1 頁 共 10 頁 v 1.1.1 FF301 致： ...

Core Insights - The data indicates significant trading volume increases for various companies, suggesting heightened investor interest and potential market movements [1][2][3][4][5] Group 1: Companies with Notable Volume Increases - 阳光能源 (00757) reported a volume ratio of 2.35, indicating strong trading activity [2] - 长城汽车 (02333) had a volume ratio of 2.21, reflecting increased investor engagement [2] - 郑煤机 (00564) showed a volume ratio of 1.92, suggesting a notable rise in trading [2] Group 2: Additional Companies with Increased Trading Activity - 万国数据-SW (09698) recorded a volume ratio of 1.83, indicating significant market interest [2] - 映恩生物-B (09606) had a volume ratio of 1.78, reflecting heightened trading activity [2] - 超盈国际控股 (02111) reported a volume ratio of 1.71, suggesting increased investor focus [2] Group 3: Companies with Moderate Volume Ratios - 中国能源建设 (03996) had a volume ratio of 1.70, indicating a solid level of trading activity [2] - 亚信科技 (01675) reported a volume ratio of 1.60, reflecting moderate investor interest [2] - 金宝通 (00320) showed a volume ratio of 1.53, suggesting a rise in trading volume [2] Group 4: Companies with Lower Volume Ratios - 中国水务 (00855) had a volume ratio of 1.52, indicating stable trading activity [2] - 广汽集团 (02238) reported a volume ratio of 1.52, reflecting consistent investor engagement [2] - 凯莱英 (06821) showed a volume ratio of 1.52, suggesting steady trading interest [2]

Group 1 - The monitoring report from the Chinese CDC indicates an upward trend in the COVID-19 positive rate in April, with southern provinces showing higher rates than northern ones [1] - In Hong Kong, the COVID-19 positive rate increased from 1.71% to 8.21% over four weeks, indicating a rising trend in the region [1] - Taiwan reported a significant increase in emergency visits related to COVID-19, with a 66% rise in cases and additional severe cases and deaths [1] Group 2 - The Chinese CDC reported an increase in the COVID-19 positive rate among flu-like cases in emergency departments, rising from 7.5% to 16.2% [2] - Among hospitalized severe acute respiratory infection cases, the COVID-19 positive rate increased from 3.3% to 6.3% during the monitoring period [2] - The new coronavirus has surpassed rhinovirus as the leading cause of emergency visits for flu-like cases in the specified three-week period [2] Group 3 - Relevant pharmaceutical companies in the Hong Kong stock market include Shandong Xinhua Pharmaceutical (00719), Jinhongzi (06896), Sanofi (01530), and Dongyangguang Changjiang Pharmaceutical (01558) [3]

Group 1 - The stock price of Jinsongzi (06896.HK) closed at 4.350 HKD on April 28, marking a 3.82% increase from the previous trading day and reaching a one-year high [1] - The net capital inflow for the day was 2.7694 million HKD, with 3.65548 million HKD flowing in and 886.09 thousand HKD flowing out [1] - Jinsongzi Holdings Group Limited is recognized as an outstanding technology enterprise in the national pharmaceutical industry, originally established as Liuzhou Candy Factory in March 1956 [1] Group 2 - The company focuses on the pharmaceutical and food health industries, with over sixty types of products including Jinsongzi throat lozenges and various traditional foods [2] - Jinsongzi throat lozenges are well-regarded for their effectiveness in relieving throat discomfort and have maintained a leading market share in their category, exporting to over twenty countries and regions [2] - The company has achieved multiple certifications, including GMP, HACCP, ISO9001:2000, and FDA, establishing itself as a trusted unit in quality and consumer satisfaction in China [2]

Financial Performance - The group's revenue increased by approximately RMB 223.6 million or 23.3% to approximately RMB 1,185.0 million for the year ended December 31, 2024[12]. - Gross profit rose by approximately RMB 196.5 million or 28.2% to approximately RMB 894.2 million for the same period[12]. - Profit attributable to equity holders increased by approximately RMB 68.4 million or 27.3% to approximately RMB 318.6 million[12]. - The group's revenue for the year ended December 31, 2024, was approximately RMB 1,185.0 million, an increase of about RMB 223.6 million or 23.3% compared to RMB 961.4 million for the year ended December 31, 2023, primarily due to significant sales growth of the flagship product, Jinsongzi throat lozenges (OTC)[57]. - Revenue from the sales of Jinsongzi throat lozenges (OTC) for the year ended December 31, 2024, was approximately RMB 1,095.3 million, an increase of about RMB 230.4 million or 26.6% compared to RMB 864.9 million for the year ended December 31, 2023, driven by increased advertising and promotional activities[57]. - Net profit for the year ended December 31, 2024, was approximately RMB 318.6 million, an increase of approximately RMB 68.4 million or 27.3% compared to approximately RMB 250.2 million for the year ended December 31, 2023[70]. Product Development and Innovation - The company is advancing three major innovation tracks, including sugar-free solutions and patented probiotics lozenges[14]. - The group launched a new product, Jinsongzi compound probiotic lozenges, developed in collaboration with a research team, utilizing proprietary strains and advanced technologies[52]. - The company has developed a modern integrated group primarily engaged in the production and sales of lozenges, other pharmaceuticals, and biotechnology foods[27]. - Since 1994, the company has successfully developed 32 new products, including 8 pharmaceuticals and 22 food items, enhancing its R&D capabilities[41]. - The new product Jin Sang Zi compound probiotic lozenges, developed in collaboration with Beijing Agricultural University, utilizes advanced technologies and has obtained six patents[40]. Market Expansion and Strategy - The company expanded its international marketing network to cover over 60 countries and regions across six continents[18]. - The company officially entered the South Korean market in early 2025, launching customized product combinations[18]. - The company is focused on enhancing its core competitiveness and optimizing its product system based on consumer demand[85]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of $30 million set aside for potential deals[7]. - The company aims to increase its market share by 3% in the next fiscal year through targeted marketing strategies[10]. Sales and Distribution - The flagship product, Golden Throat Lozenges (OTC), accounted for approximately 92.4% of the total revenue for the year ending December 31, 2024[31]. - The sales volume of Jinsongzi throat lozenges (OTC) reached 145,560 thousand boxes with a gross margin of 76.6% for the year ended December 31, 2024, compared to a sales volume of 118,133 thousand boxes and a gross margin of 74.8% for the previous year[59]. - The company has established a comprehensive national sales and distribution network, covering all provinces and regions in China, with significant revenue coming from distributors[45]. - As of December 31, 2024, Jin Sang Zi throat treasure products have been exported to 23 countries and regions, with new markets including India and South Korea[44]. Expenses and Financial Management - Selling and distribution expenses rose to approximately RMB 355.9 million for the year ended December 31, 2024, an increase of approximately RMB 89.5 million or 33.6% from approximately RMB 266.4 million for the year ended December 31, 2023, mainly due to increased promotional expenses[65]. - Administrative expenses increased to approximately RMB 117.1 million for the year ended December 31, 2024, up by approximately RMB 22.5 million or 23.8% from approximately RMB 94.6 million for the year ended December 31, 2023, primarily due to increased investment in R&D activities[66]. - The group's sales cost increased from approximately RMB 263.7 million for the year ended December 31, 2023, to approximately RMB 290.8 million for the year ended December 31, 2024, primarily due to the rise in sales volume of the OTC product Jinshanzui throat lozenges[60]. Corporate Governance and Shareholder Information - The board proposed a final dividend of HKD 0.5 per share, subject to shareholder approval[12]. - The company has adopted a stable dividend policy, prioritizing cash dividend distribution as a profit allocation goal[117]. - The company has confirmed the independence of all independent non-executive directors according to the criteria set out in Listing Rule 3.13[135]. - The company has established a compensation committee to develop its compensation policy based on operational performance and market practices[151]. - The company has confirmed compliance with the non-competition agreement with its controlling shareholders for the year ended December 31, 2024[171]. Future Outlook - The company provided a positive outlook for the next quarter, projecting a revenue increase of 10%[3]. - New product launches are expected to contribute an additional $50 million in revenue next quarter[4]. - The company aims to strengthen its leading position in the throat lozenge market and expand its market share in China's pharmaceutical and food sectors by 2025[85]. Related Party Transactions - The company has established related party transactions with its non-executive director, Jiang Peizhen, involving procurement and licensing agreements[172]. - The company has confirmed that all related party transactions comply with the disclosure requirements of the Listing Rules[196].

Financial Performance - The group's revenue increased by approximately RMB 223.6 million or 23.3% to approximately RMB 1,185.0 million for the year ended December 31, 2024[3]. - Gross profit rose by approximately RMB 196.5 million or 28.2% to approximately RMB 894.2 million for the same period[3]. - EBITDA increased by approximately RMB 78.3 million or 19.1% to approximately RMB 489.1 million[3]. - Profit attributable to equity holders increased by approximately RMB 68.4 million or 27.3% to approximately RMB 318.6 million[3]. - Total comprehensive income for the year was RMB 319.4 million, compared to RMB 254.8 million in the previous year[5]. - For the fiscal year ending December 31, 2024, the company's revenue was approximately RMB 1,185.0 million, an increase of about RMB 223.6 million or 23.3% compared to RMB 961.4 million for the fiscal year ending December 31, 2023[54]. - Net profit for the year ended December 31, 2024, was approximately RMB 318.6 million, an increase of approximately RMB 68.4 million or 27.3% compared to RMB 250.2 million in 2023[67]. Assets and Liabilities - Non-current assets totaled RMB 494.99 million, an increase from RMB 481.41 million in the previous year[6]. - Current assets amounted to RMB 1,756.18 million, a decrease from RMB 1,817.63 million in the previous year[6]. - Total liabilities decreased from RMB 706.89 million to RMB 700.47 million[6]. - The company's net assets decreased from RMB 1,550.70 million to RMB 1,466.30 million[7]. - The company's total borrowings increased to approximately RMB 426.9 million as of December 31, 2024, compared to RMB 412.3 million in 2023, reflecting an increase of RMB 14.6 million[69]. - The company's debt-to-equity ratio rose from approximately 26.6% as of December 31, 2023, to approximately 29.1% as of December 31, 2024[71]. Revenue Sources - Revenue from mainland China was RMB 1,178,108 thousand in 2024, up 24.0% from RMB 951,639 thousand in 2023[14]. - Revenue from a major customer (Customer A) accounted for RMB 148,375 thousand in 2024, an increase of 15.7% from RMB 128,285 thousand in 2023[16]. - Revenue from the sales of Jin Sangzi throat lozenges (OTC) for the fiscal year ending December 31, 2024, was approximately RMB 1,095.3 million, an increase of about RMB 230.4 million or 26.6% from RMB 864.9 million for the previous year[54]. - The flagship product, Jin Sangzi throat lozenges (OTC), accounted for approximately 92.4% of total revenue in the fiscal year ending December 31, 2024[37]. Expenses and Costs - Research and development costs rose to RMB 32,418 thousand in 2024, significantly higher than RMB 17,073 thousand in 2023, marking an increase of 90.1%[20]. - Total financial costs increased to RMB 15,363 thousand in 2024, up from RMB 10,699 thousand in 2023, representing a 43.5% rise[21]. - Income tax expense for 2024 was RMB 118,647 thousand, compared to RMB 110,859 thousand in 2023, indicating a 7.0% increase[22]. - Sales and distribution expenses increased to approximately RMB 355.9 million, a rise of approximately RMB 89.5 million or 33.6% from RMB 266.4 million in 2023, primarily due to increased promotional expenses[62]. - Administrative expenses rose to approximately RMB 117.1 million, an increase of approximately RMB 22.5 million or 23.8% from RMB 94.6 million in 2023, mainly due to higher investment in R&D activities[63]. Dividends - The board proposed a final dividend of HKD 0.5 per share, subject to approval at the upcoming annual general meeting[3]. - Proposed final dividend for 2024 is RMB 342,312 thousand, down from RMB 401,982 thousand in 2023, reflecting a decrease of 14.8%[22]. - The board proposes a final dividend of HKD 0.5 per share for the year ended December 31, 2024, subject to shareholder approval[85]. Product Development and Innovation - The company aims to leverage advanced technologies in product development, including patented probiotics and innovative encapsulation techniques[40]. - The new product "Jin Sang Zi Chang Bao" has passed testing and entered the Hong Kong market in March 2024[40]. - The company has received six patents for its active probiotics used in the newly developed Jin Sangzi compound probiotic lozenges, indicating a strong commitment to R&D[49]. - The company is focusing on developing new products such as gene drugs, traditional Chinese medicine formulas, and specialty health foods to drive growth in the health industry[53]. Market Strategy and Expansion - The company has established a comprehensive national sales and distribution network, covering all provinces and regions in China by December 31, 2024[45]. - The company has expanded its international strategy, with products exported to 23 countries and regions by December 31, 2024, including new markets like India and Korea[44]. - The company has developed a strong online presence, with nearly 100 million total views on its YouTube channel and over 4.5 million video views[44]. - The company has signed promotional cooperation agreements with 11 promoters to enhance local market penetration[47]. - The company plans to enhance its core competitiveness over the next decade by focusing on health services and expanding its market share in throat lozenges and other pharmaceutical products[79]. Corporate Governance and IPO - The company has adopted a corporate governance code to ensure high standards of governance and protect shareholder interests[86]. - The net proceeds from the initial public offering (IPO) after deducting underwriting fees and related expenses amount to approximately HKD 909.6 million[80]. - As of December 31, 2024, the company has utilized approximately HKD 731.3 million, representing about 80.4% of the IPO proceeds[80]. - The board will continuously evaluate the use of the net proceeds from the IPO to adapt to changing market conditions and improve performance[82].